Precision Oncology Today
The field of exposomics is still in its early stages. Pioneering researchers are grappling with methods to marry multi-omic datasets, blood and urine mass spectrometry data, and even postal code and satellite data to gain insights into the highly complex interface between human biology and environmental exposures--and how it affects human health and wellness.
Inside Precision Medicine’s editor in chief, Damian Doherty, spoke to Werner, Alltrna's CEO, about her career, her motivation to lead this company, and what rare disease means to her on a personal level.
Trending on Inside Precision Medicine
Results of the pivotal ATOMIC-Meso trial show that adding the arginine-depleting agent pegargiminase to standard platinum and pemetrexed chemotherapy significantly improves survival in patients with nonepithelioid pleural mesothelioma.
A light-triggered device that is thinner than a human hair can be used to control electrical activity in the body like cardiac pacemakers.
A new position statement published today in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism states that diabetes care is more effective when the patient experience is taken into account when formulating a treatment plan.